Medical imaging in clinical trials reduces costs and improves time to market, but many biopharma companies leave these benefits on the table
Medical imaging artificial intelligence (AI), specifically AI-driven image biomarkers, is transforming researchers’ ability to mine knowledge and insights from medical image reading for complex diseases (MS, Alzheimer’s, other CNS, oncology, etc.). AI biomarkers offer precision, quantification, and reproducibility to accelerate and deepen the understanding of medical imaging results.
An underrated, and often overlooked, component of the clinical trial workflow relates to the upstream application of AI to the management of medical images, before the downstream application of biomarkers. AI tools exist to expedite and support the collection, cataloguing, quality control, and synthesis of complex imaging and associated clinical data in a single, scalable digital environment. In addition, these purpose-built solutions, which prepare the images for AI biomarker analysis, also integrate those very biomarkers into the same platform to facilitate and simplify execution of the AI analytics. The application of an integrated AI solution that spans the entire imaging workflow represents the state of the art for optimizing the benefits of complex medical imaging in clinical trials – image collection and processing speed and efficiency integrated in the same system with the precision and quantification of AI-powered biomarkers.
Powerful software solutions that manage the entire medical imaging workflow for clinical trials allow researchers to spend more of their time discovering previously undetectable insights (generated from these tools), rather than on data manipulation and administration.
Read the full article in the latest edition of International Clinical Trials with exclusive content from IQVIA, IBM Watson Health and QMENTA: Read Here